NEWSROOM

Re-Stem Biotech Awarded 2020 Ernst & Young Fudan “China’s Most Promising Company” Award

0 Comments

SUZHOU, China, October 14, 2020 (PRLOG) – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury

Read Full

Re-Stem-Funded Study Targeting Mitochondrial Dysfunction in Aging and Age-Related Diseases Published in Science Advances Journal

0 Comments

SUZHOU, China – Aug. 9, 2020 – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury and various cancers

Read Full

Re-Stem Biotech Provides Banking of Immune Cells for Medical Staff in Hubei

0 Comments

SUZHOU, China – Feb. 11, 2020 — Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and products for various indications, including osteoarthritis, stroke,

Read Full

Re-Stem Biotech Receives GMP Certification of its Upgraded Cleanrooms in Suzhou

0 Comments

SUZHOU, China – Dec. 11, 2019 – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and products for various indications, including osteoarthritis, stroke, spinal

Read Full

Re-Stem Biotech Signs Cooperation Agreement with International Health Industry Park in Wuhan, China

0 Comments

SUZHOU, China – Nov. 1, 2019 – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and products for various indications, including osteoarthritis, stroke, spinal

Read Full

Re-Stem Biotech Research Collaboration Featured on Johns Hopkins Technology Ventures’ Website

0 Comments

SUZHOU, China – Sept. 19, 2019 – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis,

Read Full

Re-Stem Biotech Expands Cell Manufacturing and Banking Facilities to Kunming, China

0 Comments

SUZHOU, China – August 22, 2019 (PRLOG) – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for

Read Full

Re-Stem Biotech to hold Grand Opening of New Location and Expansion of its Corporate Office and R&D

0 Comments

VIEW ON PRLOG SUZHOU, China – May 15, 2019 (PRLOG) – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and

Read Full

Re-Stem Biotech Sponsors Guangdong Private Entrepreneurs Golf Association Invitational Tournament

0 Comments

VIEW ON PRLOG SUZHOU, China – April 2, 2019 (PRLOG) – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies

Read Full

Re-Stem Biotech Publication In “Nature Neuroscience” Related to Spinal Cord Injury Treatment

0 Comments

VIEW RELEASE ON PRLOG SUZHOU, China, February 25, 2019 (PRLOG) – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell therapies targeting

Read Full